Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.

Abstract	We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.
Authors	Ralph Corey, Gregory Moran, Richard Goering, Mekki Bensaci, Taylor Sandison, Carisa De Anda, Philippe Prokocimer
Journal	Diagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) Vol. 94 Issue 3 Pg. 277-286 (Jul 2019) ISSN: 1879-0070 [Electronic] United States
PMID	30940414 (Publication Type: Journal Article)
Copyright	Copyright © 2019 Elsevier Inc. All rights reserved.
Chemical References	Anti-Bacterial Agents Oxazolidinones Tetrazoles tedizolid Linezolid
Topics	Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents (administration & dosage) Child Clinical Trials, Phase III as Topic Double-Blind Method Female Gram-Positive Bacterial Infections (drug therapy) Humans Linezolid (administration & dosage) Male Middle Aged Oxazolidinones (administration & dosage) Randomized Controlled Trials as Topic Skin Diseases, Bacterial (drug therapy) Soft Tissue Infections (drug therapy) Tetrazoles (administration & dosage) Treatment Outcome Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!